Dr. Jianbin Zheng earned his PhD in medicinal chemistry at Fudan University in Shanghai, China, where he studied rational drug design, synthesis and evaluation of anti-cancer and central nervous system (brain and spinal cord; CNS) drugs. Following his doctoral work, Dr. Zheng began working on drug discovery projects as a principal investigator at the East China University of Science and Technology in Shanghai. Using computer-aided drug design and organic synthesis, his main research interests involve developing programs in pre-clinical drug discovery, including hit-to-lead optimization, drug-protein interaction and structure-based drug design for CNS diseases, cancer and diabetes. In 2012, Dr. Zheng studied a new methodology for enzyme synthesis at Yale University as a visiting scholar. Since 2013, his research has focused on the design, synthesis and mechanism of beta-glucocerebrosidase (GCase) (an enzyme that breaks down fats) for Gaucher's disease (in which fatty substances build up in the body) and Parkinson's disease at Northwestern University.